STOCK TITAN

LeMaitre Vascular (LMAT) Stock News

LMAT NASDAQ

LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.

Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.

Rhea-AI Summary

LeMaitre Vascular (LMAT) announced that management will participate in three upcoming investor conferences, with CFO Dorian LeBlanc presenting at each.

The schedule is Stifel in New York on November 12, 2026, at 8:00 AM EST; Jefferies in London on November 17, 2026, at 10:30 AM GMT; and Piper Sandler in New York on December 3, 2026, at 8:30 AM EST.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
-
News
Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) reported third-quarter 2026 sales of $68.0 million, up 11% from the same quarter last year. Organic growth was 12%, comprising 7% pricing and 5% unit growth. Gross margin fell to 71.7% from 75.3%, but rose from 70.8% excluding the prior-year employee retention tax credit. Operating income fell 13% to $17.7 million; diluted EPS was $0.65 versus $0.75.

In October, LeMaitre acquired vascular assets from B. Braun for $19.2 million. The products generated $9.4 million in 2025 sales outside North America; sales will transition into LeMaitre’s channel over 18–24 months. The company forecasts full-year sales of $274.8–$276.8 million and EPS of $2.77–$2.82, including the acquisition. Cash and short-term securities totaled approximately $390 million at September 30. A $0.25 quarterly dividend is payable December 3, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
-
Rhea-AI Summary

LeMaitre Vascular (LMAT) will release its third quarter 2026 financial results after the market close on November 4, 2026. A conference call at 5:00 PM EST that day will cover the results, business highlights and company outlook. A live audio webcast and replay will be available at ir.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
earnings date
Rhea-AI Summary

LeMaitre (Nasdaq: LMAT) announced that its CFO, Dorian LeBlanc, will participate in three investor conferences in September 2026. He is scheduled for Fireside Chats at the Wells Fargo 21st Annual Healthcare Conference on September 8 in Boston, the Morgan Stanley 24th Annual Global Healthcare Conference on September 16 in New York City, and the 19th Annual Barrington Research Virtual Fall Investment Conference on September 22, with the time to be announced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
Rhea-AI Summary

LeMaitre (Nasdaq: LMAT) announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026. The event will be held in a virtual format.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
News
Rhea-AI Summary

LeMaitre (Nasdaq: LMAT) reported Q2 2026 net sales of $70.4m, up 10% year over year (+10% organic). Gross margin rose 210 bps to 72.1%, driving operating income to $20.4m (+26%) and diluted EPS to $0.74 (+23%). Cash and marketable securities increased $9.0m sequentially to $376.2m.

Artegraft sales grew 34%, now approved in 56 countries and representing 21% of sales. Grafts (+23%), carotid shunts (+18%), patches (+4%) and all regions posted record sales, while catheters declined 11%, making organic growth 12% excluding catheters.

For 2026, LeMaitre guides midpoints of $276.3m sales (+11% reported and organic), 72.4% gross margin, $76.8m operating income (+13%, +19% adjusted) and $2.89 EPS (+15%, +21% adjusted). The board approved a $0.25 quarterly dividend payable September 3, 2026 and has an authorized $100m share repurchase program through February 18, 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.32%
Tags
Rhea-AI Summary

LeMaitre (Nasdaq: LMAT) will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. The company will host a conference call at 5:00 PM EDT the same day to review results, business highlights, and outlook.

Investors can access the live call by registering online to receive dial-in details and a PIN. An audio webcast, including a replay, will be available at ir.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
earnings date
-
Rhea-AI Summary

LeMaitre (Nasdaq:LMAT) announced that management will participate in two investor conferences in June 2026.

They will join the Jefferies Global Healthcare Conference in New York on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference in Miami Beach on June 10, 2026, with scheduled presentations at each event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026 at 5:15 PM PT. Management presentation details and timing are provided for investors and analysts ahead of the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
none
News
Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) reported Q1 2026 results: sales $66.6M (+11%, +10% organic), gross margin 72.7% (+350 bps), operating income $17.8M (+41%), and EPS $0.68 (+42%). Cash balance rose to $367.2M. Company declared a $0.25 quarterly dividend and authorized a $100M share repurchase program. Full‑year guidance midpoint: $280M sales, gross margin ~72.3%, and adjusted EPS midpoint $3.00.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags

FAQ

What is the current stock price of LeMaitre Vascular (LMAT)?

LeMaitre Vascular (LMAT) last closed at $74.86.

What is the market cap of LeMaitre Vascular (LMAT)?

The market cap of LeMaitre Vascular (LMAT) is approximately $1.7B.